• Journal of Medicine and Life Science
• /
• 제16권2호
• /
• pp.46-51
• /
• 2019

Inflammatory bowel disease (IBD) is an immune-mediated chronic inflammatory intestinal condition. With development of various treatment options for IBD, 5-aminosalicylic acid (5-ASA) agents became the drugs of choice due to high efficacy and low risk of complication, specifically effective at inducing and maintaining remission in ulcerative colitis(UC). Pancytopenia caused by 5-ASA agents, especially by mesalazine, has been rarely reported compared with azathioprine, which is commonly used for glucocorticoid-dependent IBD and known to have risk of bone marrow suppression. In the present report, we describe the case of a 57-year-old woman diagnosed with UC, who developed pancytopenia due to adverse effect of mesalazine after recovery from azathioprine-induced pancytopenia. After withdrawal of mesalazine, the laboratory values consistent with myelosuppression continued for 3 months while pancytopenia from azathioprine remained only for 2 weeks. Since pancytopenia can be fatal due to its risk of severe bleeding and infection, close monitoring of clinical presentation is important when starting mesalazine and laboratory data should be evaluated whenever the patients present related symptoms. Furthermore, we suggest that complete blood cell counts should be considered when resuming mesalazine following the development of pancytopenia from any cause, as routinely recommended for azathioprine use.

• Tuberculosis and Respiratory Diseases
• /
• 제51권5호
• /
• pp.474-481
• /
• 2001

염증성 장질환 환자에서 폐주변부에 발생하는 진행성 폐침윤과 기침, 발열, 호흡곤란 등의 호흡기계 증상, 말초혈액내 호산구중다중의 발현, 다른 호산구중다중을 유발할 만한 약제나 기생충 감염 등의 원인이 없는 경우에 메살라진이나 설파살라진에 의한 호산구성 폐렴의 가능성율 생각하고, 약제 투여 중단과 스테로이드 사용을 고려해야 하며, 기관지경을 통한 기관지 폐포액에서 호산구 증가와 lymphocyte stimulation test, 폐생검올 통해 진단할 수 있다. 저자들은 궤양성 대장염 환자에서 부작용이 적다고 알려진 메살라진에 의한 호산구성 폐렴 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

• Biomolecules & Therapeutics
• /
• 제23권5호
• /
• pp.486-492
• /
• 2015

Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their interassay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery.

• Tuberculosis and Respiratory Diseases
• /
• 제62권1호
• /
• pp.56-61
• /
• 2007

궤양성 대장염은 장내 염증으로 국한되지 않고 관절, 피부, 눈, 간 및 담도계 등의 다양한 장외 장기를 흔하게 침범하는 것으로 알려져 있다. 그러나, 궤양성 대장염에 폐질환이 동반되는 경우는 흔치 않고 특히 간질성 폐렴의 병발은 전세계적으로 매우 드물며, 국내에서 수술적 폐생검으로 확진된 비특이적 간질성 폐렴과 동반된 궤양성 대장염 환자는 현재까지 보고 된 바 없다. 저자들은 호흡기 증상 없이 우연히 흉부 방사선촬영의 이상소견으로 입원하여 수술적 폐생검으로 확진된 비특이적 간질성 폐렴과 동시에 활동성 궤양성 대장염을 진단받은 후, prednisolone (1mg/kg)과 함께 mesalazine 병용 치료를 시작해서 비특이적 간질성 폐렴과 궤양성 대장염 모두 호전중인 환자 1예를 경험하여 이를 문헌 고찰과 함께 보고하는 바이다.

• 한국산학기술학회:학술대회논문집
• /
• 한국산학기술학회 2009년도 추계학술발표논문집
• /
• pp.318-321
• /
• 2009

The Efficacy of PSB-2061, was investigated in comparision with predinisolone in acetic acid and Picrylsulfonic acid solution (TNBS)-induced rat inflammatory bowel disease (IBD) for 5 days. 5 % TNBS solution were administered with polyethylene (P.E) tube inserted to rats intracolon, which causing colitis to the rats. The TNBS control group (the saline treated colitic rat) exhibited ulceration and inflammation of the distal colon with formation of granuloma and pathologic connections. We checked the inflammatory parameters like rat's weight, food intake quantity change during administration. After 5 days, we sacrificed the rats and checked the colon's length, ulcer and pathologic condition. Oral treatment with PSB-2061 resulted in significant recovery of macroscopic parameters like weight and diet intake change. Especially, PSB-2061 extract had a more potent effect than $mesalazine^{(R)}$ on macroscopic colonic damage score. We can suggest that PSB extract could be a promising drug in the treatment of IBD.

• Clinical and Experimental Pediatrics
• /
• 제49권1호
• /
• pp.107-111
• /
• 2006

크론병은 매우 드문 질환이나 지난 10년간 발생률이 꾸준히 증가하고 있다. 저자들은 골수 이형성 증후군을 가진 환아에서 크론병이 발병한 2례를 소아에서는 최초로 보고하는 바이다. 첫번째 환아는 3세에 골수 이형성 증후군으로 진단받았고, 수 년간 지속된 반복적인 복통 및 설사, 혈변, 성장 부전이 있어 8세에 크론병으로 진단받았다. 대장 내시경 검사에서는 맹장에서 오름 결장에 걸쳐 조약돌상 점막과 표재성 궤양 및 염증성 삼출이 있었으며, 조직 소견은 궤양 사이에 정상 점막을 포함하고 있으면서 림프구 침윤을 보였다. Mesalazine과 deflazacort로 치료 후 증상은 호전을 보였다. 두 번째 환아는 9세에 골수 이형성증후군으로 진단받았으며, 13세에 반복되는 혈변과 복통, 구토, 발열로 크론병으로 진단받았다. 대장 내시경 검사에서 크고 깊은 경화성 궤양이 회맹판에서 맹장 쪽 주위에서 발견되었다. 이 외의 부위에는 병변이 없어 병변을 절제하였고, 조직은 경벽 염증과 림프구 집합을 동반한 궤양 소견을 보였다. 절제술 후 증상은 호전을 보였다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제8권1호
• /
• pp.70-75
• /
• 2005

저자들은 기존의 크론병 치료에 호전이 없었던 항문 주위 병변에 0.3 mg/g의 저농도 tacrolimus 연고제를 1일 2회 환부에 도포하는 방법으로 약물에 의한 부작용 발생 없이 병변의 현저한 호전을 보인 3례를 경험하였기에 보고하는 바이다.

• Biomolecules & Therapeutics
• /
• 제5권2호
• /
• pp.165-173
• /
• 1997

This study was conducted to investigate the effect of DA-9601, an extract of Artemisiae Herba, which is known to possess mucoprotective action either by free radical scavenging effect or increase of mucus secretion, against animal models of inflammatory bowel disease (IBD) induced by trinirobenzene sulfonic acid (TNBS) or other noxious agents. Experimental colitis was induced by intracolonic administration of TNBS in 50% ethanol, or 1 ml of 7% acetic acid solution (AA), by subcutaneous injection of indomethacin (INDO) in rats, or by supplementing drinking water with 5% dextran sodium sulfate (DSS) in albino mice. DA-9601 was treated orally for 4 to 7 days. Animals were euthanized 1 day after the last treatment for morphological and biochemical analysises. All the noxious agents including TNBS, AA, INDO and DSS elicited severe colitis. The animals treated with DA-9601 showed a consistent, dose-related reduction in the severity of colitis, grossly and histologically. The reduction was significant (p<0.05) after administration of DA-9601 at dose range of 10 mg/kg or above. In TNBS-induced colitis, the rats receiving DA-9601 showed significantly decreased mucosal myeloperoxidase (MPO) and thiobarbituric acid-reactive substances (TBA-RS), when compared to control and mesalazine groups. Mucosal proinflammatory cytokine levels were also decreased after DA-9601 treatment. In conclusion, DA-9601 ameliorated macroscopic and histologic scores in experimental colitis either through decreasing oxidative stress or by attenuating cytokines involved in inflammation. DA-9601 could be a promising drug for the therapy of IBD.

• Biomolecules & Therapeutics
• /
• 제21권5호
• /
• pp.398-404
• /
• 2013

During a screening program to search the anticolitic herbal medicines, 80% ethanol extract of the rhizome of Anemarrhena asphodeloides (AA) was found to potently inhibit the expression of proinflammatory cytokines TNF-${\alpha}$ and IL-1${\beta}$, as well as the activation of NF-${\kappa}B$ in LPS-stimulated colonic macrophages, followed by that of the rhizome of C. chinensis (CC). AA also potently inhibited TNBS-induced colitic markers, shortening of the colon and increase of macroscopic score, myeloperoxidase activity, TNF-${\alpha}$, IL-1${\beta}$, and IL-6, in mice. The synergistic effect of CC against the anticolitic effect of AA was investigated. CC synergistically inhibited the anticolitic effect of AA. AC-mix (AA+CC, 1:1) potently inhibited them. AC-mix also inhibited the activation of NF-${\kappa}B$, as well as the expression of TNF-${\alpha}$, IL-1${\beta}$, IL-6, iNOS and COX-2. The effects of AC-mix against oxazolone-induced colitis were investigated in mice. AC-mix also potently inhibited oxazolone-induced inflammatory markers, colon shortening, macroscopic score, myeloperoxidase activity, NF-${\kappa}B$ activation and proinflammatory cytokines. Overall, the anti-colitic effect of AC-mix was superior to that of mesalazine. Based on these findings, AC-mix may improve colitis by inhibiting NF-${\kappa}B$ activation.

• Journal of Yeungnam Medical Science
• /
• 제25권2호
• /
• pp.182-186
• /
• 2008

Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract that affects the large bowel. Its etiology remains controversial. However, an infectious or immunologic origin is considered the primary cause. The onset of UC is typically slow and insidious, but some patients may present acutely with symptoms mimicking infectious colitis. We report a case of ulcerative colitis mimicking acute hemorrhagic colitis at initial presentation. A 60-year-old man was referred to Yeungnam University Hospital for bloody diarrhea and abdominal pain. Sigmoidoscopy revealed mildly edematous mucosa in the rectum and hyperemic mucosa with petechiae in the sigmoid colon. The patient was treated with antibiotics for several days, and his symptoms improved. However, after one month, his bloody diarrhea relapsed. Follow-up sigmoidoscopy revealed mucosal friability in the rectum and sigmoid colon. He was diagnosed with ulcerative colitis, and his symptoms were improved with mesalazine and a steroid enema.